Top advances in lung cancer, 2021

Nisha A. Mohindra, Jyoti D. Patel*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first-in-class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung cancer. Lay summary: There has been tremendous innovation in the treatment of nonsmall cell lung cancer. The year 2021 was marked by new approaches to adjuvant therapy and the availability of agents to target new subsets of nonsmall cell lung cancer.

Original languageEnglish (US)
Pages (from-to)3434-3437
Number of pages4
JournalCancer
Volume128
Issue number19
DOIs
StatePublished - Oct 1 2022

Keywords

  • HER2
  • Kirsten rat sarcoma (KRAS)
  • adjuvant therapy
  • epidermal growth factor receptor (EGFR) exon 20
  • lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Top advances in lung cancer, 2021'. Together they form a unique fingerprint.

Cite this